Drug candidates

The newest addition to the free DDW podcast is the In Conversation With series, where DDW speaks with members of the drug discovery industry about their work and how it helps turn science into business.    In this latest episode, DDW’s Megan Thomas speaks with Dr Mark Varney, the Chief Scientific Officer at PsychoGenics, who discusses […]

Evotec has entered into a drug discovery collaboration with Eli Lilly and Company (Lilly) in the field of metabolic diseases with a focus on kidney diseases and diabetes.  The collaboration  The collaboration leverages Evotec’s metabolic disease experience, as well as its kidney disease patient database, to identify and validate promising novel targets for therapeutic intervention. […]

German independent research institute BioMed X has announced the launch of a global call for application to identify biomedical scientists and inventors to form a new startup at AION Labs’, Israel. The company spearheads the adoption of AI technologies and computational science to solve therapeutic challenges.  The chosen AION Labs startup team will be sponsored by several industry partners and supported by the Israel Innovation Authority (IIA). The […]

AlzeCure Pharma has dosed the first patient in the company’s next clinical Phase I study (multiple ascending dose, MAD) with the candidate drug ACD856, focused on Alzheimer’s disease. ”It is satisfying that the clinical development program is proceeding according to plan and that we have now begun this follow-up Phase I study where we will […]

Exscientia has entered into a collaboration agreement with Bristol-Myers Squibb Company. The collaboration will use AI to accelerate the discovery of small molecule therapeutic drug candidates in multiple therapeutic areas, including oncology and immunology. This expanded collaboration builds upon Exscientia’s existing collaboration with Bristol Myers Squibb that was initiated in 2019. Exscientia will take responsibility […]

Eli Lilly and Company and MiNA Therapeutics have created a global research collaboration to develop novel drug candidates using MiNA’s proprietary small activating RNA (saRNA) technology platform. MiNA will utilise its saRNA platform to research up to five targets selected by Lilly that aim to address diseases across Lilly’s key therapeutic focus areas. Lilly will […]

Viswa Colluru, PhD, founder and CEO of Enveda Biosciences talks to Lu Rahman about the company’s chemical search engine and its work harnessing the complexity of the natural world to tackle today’s biggest healthcare challenges.  LR: Describe what Enveda does and some of its current work / initiatives. VC: Enveda is building the first high-resolution […]

Clinical stage gene therapy company, Ilya Pharma, has released further results from the first in human (FIH) trial of ILP100 for treating difficult and chronic wounds. ILP100 represents a new-in-class drug candidate, engineering Limosilactobacillus reuteri bacteria to produce and release the key human chemokine CXCL12 at the wound site. After delivery, ILP100 enhances the healing properties of immune cells in the wound. The company reported safety […]

Evotec has entered into an integrated multi-target drug discovery agreement with biotech venture creation firm Related Sciences to generate multiple drug development candidates, biomarkers, and IND filings over a multi-year period. Evotec and Related Sciences will jointly discover and develop a range of therapeutic approaches for clearly defined patient populations with significant unmet medical needs. […]

One Nucleus has revealed the finalists of its annual BioNewsRound Award, recognising life science companies with exciting developments. The finalists will pitch in the lead up to Genesis 2020 during which the winner will be announced. Companies and research organisations were nominated for their most important updates from the last year. These were assessed based […]

A new drug had been developed which can be applied to the skin to help prevent organ transplant recipients from developing harmful skin cancers. The world-first treatment being developed at The University of Queensland is said to be the only drug of its type that could prevent the incidence of skin cancers for transplant patients. […]

In a recent study, a research group led by Christian Gruber at MedUni Vienna’s Institute of Pharmacology isolated a peptide (small protein molecule) from beetroot. The peptide is able to inhibit a particular enzyme that is responsible for the breakdown of messenger molecules in the body. Due to its particularly stable molecular structure and pharmacological […]

4D pharma, a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs) – a novel class of drug derived from the microbiome – and Longevity Acquisition a NASDAQ-listed Special Purpose Acquisition Company (SPAC), have announced a proposed merger. The deal is worth up to $37.6 million to 4D pharma. As a result of the […]

BioIVT has launched the HEPATOMUNE kit, a long-term, stable, in vitro model for evaluating immune-related and inflammation-mediated liver injury. Hepatomune cultures are composed of hepatocytes, stromal cells and Kupffer cells in a tri-culture, mimicking the physiological microenvironment of the liver, and providing an optimal model for studying cytokines and cytokine modulators. Cytokines have important roles […]

Lu Rahman looks at the drug repurposing market. How attractive a proposition is it financially?  More than ever the world is watching drug development and is aware of the time it takes to get a drug to market. The 10-15 years that this can involve is costly, so unsurprisingly, drug repurposing has become a credible […]